We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Research Highlights.
- Authors
G. T .O; M. Z.; L. D.; K. A.; T. M.
- Abstract
The article presents an update of latest research in biotechnology. Current tests for Alzheimer disease, based on cognitive and neurological assessments and in vivo brain imaging, are not entirely accurate; a definitive diagnosis can be made only with post-mortem brain samples. A better approach might be to detect protein markers of the disease, such as amyloid-β-diffusable ligands (ADDLs), in cerebrospinal fluid, but the concentrations of these markers are too low to be detected by existing assays. Glycosylation was once thought to be the domain of eukaryotes. However, studies of bacterial antigens, like the O antigen of Gram-negative bacteria, show that glycosylation confers important functions to bacterial proteins.
- Subjects
BIOTECHNOLOGY; ALZHEIMER'S disease; CEREBROSPINAL fluid; BACTERIAL antigens; CHEMICAL engineering; ESTERIFICATION
- Publication
Nature Biotechnology, 2005, Vol 23, Issue 3, p311
- ISSN
1087-0156
- Publication type
Article
- DOI
10.1038/nbt0305-311